Search results
Results From The WOW.Com Content Network
The combination was approved for medical use in the United States in December 2024. [2] [3] ... and deutivacaftor combination therapy orphan drug designation. [5 ...
Zenocutuzumab was approved for medical use in the United States in December 2024. [3] [4] [5] It is the first approval by the US Food and Drug Administration (FDA) of a systemic therapy for people with non-small cell lung cancer or pancreatic adenocarcinoma harboring an neuregulin 1 gene fusion. [3] The FDA considers it to be a first-in-class ...
Berdazimer sodium was approved for medical use in the United States in January 2024. [ 4 ] [ 5 ] [ 6 ] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication . [ 7 ]
Zanidatamab was approved for medical use in the United States in November 2024. [ 2 ] [ 4 ] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication . [ 5 ]
Mavorixafor, sold under the brand name Xolremdi, is a medication used for the treatment of WHIM syndrome. [1] It is a CXC chemokine receptor 4 antagonist. [1] It is taken by mouth. [1]
Crovalimab was approved for use in China in February 2024, [5] in Japan in April 2024, [6] in the United States in June 2024, [7] [8] and in the European Union in August 2024. [ 2 ] [ 3 ] It was developed and is marketed by Roche / Genentech .
The oral drug, branded as Miplyffa, has now been approved for the treatment of Neimann-Pick disease type C - a rare genet US FDA approves Zevra's treatment for rare genetic disease Skip to main ...
Pegulicianine was approved for medical use in the United States in April 2024. [1 ... Clinical trial number NCT03686215 for "Investigation of Novel Surgical ...